An artificial intelligence technique for detecting DNA fragments shed by tumors and circulating in a patient’s blood, developed by Johns Hopkins Kimmel Cancer Center investigators, could help clinicians more quickly identify and determine if pancreatic cancer therapies are working.
Researchers at Baylor College of Medicine and collaborating institutions investigated for the first time in cancer the association between two sources of genetic variation: germline or inherited structural variation, which refers to large differences in the DNA sequence, and DNA methylation, which is when genes are turned on or off without altering the DNA code.
A Johns Hopkins Medicine-led research team has identified a recurrent frameshift mutation, called F722fs, in the MMS22L gene among men of Ashkenazi Jewish ancestry that is associated with a higher risk of prostate cancer and increased sensitivity to a specific anticancer therapy.
A team led by researchers at Baylor College of Medicine has identified flavonoids, natural compounds found in plants, that are toxic to bladder cancer cells cultured in the lab.
Researchers at The Wistar Institute have identified a previously unknown mechanism by which viruses can reprogram mitochondrial structure to silence immune responses and ensure successful viral reproduction.
A widely used antidepressant drug could help the immune system fight cancer, according to a new research study from UCLA.
Mayo Clinic researchers have established the world’s first biobank of human salivary gland tissue-organoids to study chronic dry mouth, or xerostomia, an agonizing side effect of damaged salivary glands that affects millions.
Researchers at the University of Chicago Medicine Comprehensive Cancer Center have discovered that high doses of radiation cause growth in existing metastatic tumors that weren’t directly treated with radiation.
For men who undergo a radical prostatectomy for the treatment of prostate cancer, post-surgery radiation therapy can play a vital role in reducing the risk of recurrence.
Artera, the developer of multimodal artificial intelligence-based prognostic and predictive cancer tests, announced the publication of a validation study in the JCO Clinical Cancer Informatics on Artera’s MMAI model.
